Regulatory Considerations for Impurity Qualification: ICH Q3A/Q3C/Q3D, RLD & MDD

  Рет қаралды 10,472

U.S. Food and Drug Administration

U.S. Food and Drug Administration

Күн бұрын

Пікірлер
Drug Substance Postapproval Changes Guidance: Determination of Impurity Profile Equivalence
23:25
Drug Substance Postapproval Changes Guidance: Determination of Impurity Profile Equivalence
U.S. Food and Drug Administration
Рет қаралды 4,3 М.
CMC Considerations for CAR T Cell Product Development
29:42
CMC Considerations for CAR T Cell Product Development
U.S. Food and Drug Administration
Рет қаралды 12 М.
БРАТТАР ИЛИ БРАКТАР | bayGUYS | 28 шығарылым
25:59
БРАТТАР ИЛИ БРАКТАР | bayGUYS | 28 шығарылым
bayGUYS
Рет қаралды 558 М.
Wednesday Shot by country - Ohio in real life #trending #funny #wednesday
0:23
Wednesday Shot by country - Ohio in real life #trending #funny #wednesday
Watch Me
Рет қаралды 22 МЛН
The Lost World: Living Room Edition
0:46
The Lost World: Living Room Edition
Daniel LaBelle
Рет қаралды 27 МЛН
From Trash to Fashion! Watch How Create Stunning Applique Dresses Out of Garbage #Shorts
1:00
From Trash to Fashion! Watch How Create Stunning Applique Dresses Out of Garbage #Shorts
5-Year Crafts
Рет қаралды 56 МЛН
Administrative Aspects of Managing a Drug Master File (DMF)
23:56
Administrative Aspects of Managing a Drug Master File (DMF)
U.S. Food and Drug Administration
Рет қаралды 3,5 М.
Regulatory Highlights for Biosimilars and Interchangeables (9of15) REdI - May 29-30, 2019
42:43
Regulatory Highlights for Biosimilars and Interchangeables (9of15) REdI - May 29-30, 2019
U.S. Food and Drug Administration
Рет қаралды 4,9 М.
Overview of the Quality System Regulation
24:20
Overview of the Quality System Regulation
U.S. Food and Drug Administration
Рет қаралды 18 М.
Decrease RTR, IR, and CR Due to Dissolution Deficiencies (21of28) GDF - Apr. 3-4, 2019
35:21
Decrease RTR, IR, and CR Due to Dissolution Deficiencies (21of28) GDF - Apr. 3-4, 2019
U.S. Food and Drug Administration
Рет қаралды 1,8 М.
Designing First-In-Human Trials for Small Molecules and Biologics
37:34
Designing First-In-Human Trials for Small Molecules and Biologics
U.S. Food and Drug Administration
Рет қаралды 11 М.
ICH M7(R1) - Chemistry and Manufacturing Control (CMC) Perspective on Hazard Assessment
20:33
ICH M7(R1) - Chemistry and Manufacturing Control (CMC) Perspective on Hazard Assessment
U.S. Food and Drug Administration
Рет қаралды 7 М.
National Drug Code (NDC) for Healthcare Providers
41:59
National Drug Code (NDC) for Healthcare Providers
U.S. Food and Drug Administration
Рет қаралды 695
Application of (Q)SAR and Expert Knowledge for ICH M7 Impurity Classification
25:35
Application of (Q)SAR and Expert Knowledge for ICH M7 Impurity Classification
U.S. Food and Drug Administration
Рет қаралды 3,8 М.
Common CMC Issues in Type II DMFs and How to Avoid Them
26:19
Common CMC Issues in Type II DMFs and How to Avoid Them
U.S. Food and Drug Administration
Рет қаралды 2,9 М.
FDA Clinical Investigator Training Course (CITC) 2024 - Day One - Session Two
1:42:25
FDA Clinical Investigator Training Course (CITC) 2024 - Day One - Session Two
U.S. Food and Drug Administration
Рет қаралды 667
БРАТТАР ИЛИ БРАКТАР | bayGUYS | 28 шығарылым
25:59
БРАТТАР ИЛИ БРАКТАР | bayGUYS | 28 шығарылым
bayGUYS
Рет қаралды 558 М.